血清外泌体 miR-484 低表达预示卵巢癌不良预后。

Low serum exosomal miR-484 expression predicts unfavorable prognosis in ovarian cancer.

出版信息

Cancer Biomark. 2020;27(4):485-491. doi: 10.3233/CBM-191123.

DOI:10.3233/CBM-191123

PMID:32065786

Abstract

BACKGROUND

Ovarian cancer (OC) is one of the most common malignancy worldwide. Emerging evidences have demonstrated that microRNAs (miRNAs) play an important role in regulating the initiation and development of OC.

OBJECTIVE

The present study was to explore the clinical significance of serum exosomal miR-484 in OC.

METHODS

A total of 113 OC patients and 60 healthy volunteers were enrolled in this study. Quantitative real-time polymerase chain reaction (qRT-PCR) was performed to measure serum exosomal miR-484 levels in blood samples.

RESULTS

Our results showed that serum exosomal miR-484 levels were significantly lower in OC patients. Serum exosomal miR-484 was able to discriminate OC cases from controls, with an area under the receiver-operating characteristics (ROC) curve (AUC) of 0.821. Combination of serum exosomal miR-484 with CA-125 showed an elevated AUC of 0.912 in identifying OC patients from controls. Moreover, decreased serum exosomal miR-484 expression was significantly associated with aggressive clinical variables as well as shorter overall survival and progression-free survival. The OC patients with simultaneously low serum exosomal miR-484 expression and high serum CA-125 levels tended to suffer the worst clinical outcomes. The multivariate analysis confirmed that low serum exosomal miR-484 level was an independent indicator.

CONCLUSIONS

Collectively, serum exosomal miR-484 could serve as a reliable and non-invasive marker for predicting the prognosis of OC.

摘要

背景

卵巢癌（OC）是全球最常见的恶性肿瘤之一。新出现的证据表明，microRNAs（miRNAs）在调节 OC 的发生和发展中起着重要作用。

目的

本研究旨在探讨血清外泌体 miR-484 在 OC 中的临床意义。

方法

本研究共纳入 113 例 OC 患者和 60 名健康志愿者。采用定量实时聚合酶链反应（qRT-PCR）检测血液样本中血清外泌体 miR-484 水平。

结果

我们的结果表明，OC 患者血清外泌体 miR-484 水平显著降低。血清外泌体 miR-484 能够区分 OC 病例和对照组，ROC 曲线下面积（AUC）为 0.821。血清外泌体 miR-484 与 CA-125 的联合检测在识别 OC 患者与对照组方面具有更高的 AUC（0.912）。此外，血清外泌体 miR-484 表达降低与侵袭性临床变量以及总生存期和无进展生存期缩短显著相关。同时具有低血清外泌体 miR-484 表达和高血清 CA-125 水平的 OC 患者往往预后最差。多变量分析证实低血清外泌体 miR-484 水平是独立指标。